Our liquid biopsy comprehensive genomic profiling service for patients with solid tumours.1,2
This website is a global information resource. It is intended for healthcare professionals only outside of the United States of America (US) who are interested in information on Foundation Medicine®. This site is not intended to provide medical advice and/or treatment guidance. If you are a US healthcare professional click here.
This site is produced by Roche as a partner of Roche Foundation Medicine.
Assesses all four main classes of genomic alterations* in >300† cancer-related genes, including guideline-recommended genomic alterations associated with available targeted therapies in all solid tumours.1·2.4-11
The FDA-approved liquid biopsy service that reports both MSl‡ and bTMB, pan-tumour genomic signatures that may help inform eligibility for immunotherapy.1-3,19-27
High sensitivity and specificity¥ for key genomic alterations, MSI‡ and bTMB across all solid tumours.1,2
Reports Tumour Fraction, the percentage of tumour-derived circulating cell-free DNA, as a measure of the likelihood of detecting genomic alterations in the liquid biopsy sample.1,2
FoundationOne Liquid CDx requires only two tubes of b lood from a single blood draw (2 x 8.5 ml whole blood) and has a turnaround time of less than 2 weeks from receipt of the sample at our laboratory to report, thereby allowing informed treatment decisions to be made faster.1-28
This may help reduce distress that patients may experience from long waiting times for scheduling a biopsy and receiving the results associated with tissue-based testing.12-15
Approved targeted therapies and immunotherapies for the patient's genomic alterations and biomarkers are ranked alphabetically within NCCN Categories of Preference (for additional information on the NCCN therapy categories please refer to the NCCN Compendium® at www.nccn.org). Reports vary according to regional differences, e.g. EU reports list EU-approved therapy options to support clinical decision-making.‖41
When using different Foundation Medicine services across the patient journey, consistency of the reports aid comparison of the results.41,42